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GSTTI) and cytochrome P-450 (CYPIAl) loci
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Summary A case-control study was designed to identify associations between polymorphisms at p53, cytochrome P-450 (CYPlAl) and
glutathione-S-transferases and endometrial cancer susceptibility. Among all polymorphisms analysed, an insertional variant in p53 (P53PIN3)
and two polymorphisms in the 3'-end and exon 7 of CYPlAl showed significant association with enhanced endometrial cancer risk.
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Classical genetic approaches for identifying susceptibility genes,
although successful for cancer with strong familial links, have not
yet identified corresponding genes for sporadic cancers. For
example, the BRCAJ and BRCA2 genes in breast cancer and
several DNA mismatch repair genes in hereditary non-polyposis
colon cancer, although strongly associated with familial cancer,
accounts for less than 10% of non-familial malignancies
(Vogelstein et al, 1994; Marra et al, 1995; Miki et al, 1996). In
addition, phenotype variation between individuals carrying the
same mutation in a high-penetrance gene can be considerable.
Such observations have led to a number of studies attempting
to identify low-penetrance genes that modify an individual's risk
of cancer. Because sporadic cancers result from mutations in
transforming genes, and carcinogen-detoxification influences the
mutational events in these key genes, several polymorphic
carcinogen-metabolism genes are potentially useful candidates. In
this sense, three supergene families have attracted interest: phase I
cytochromes P-450 (CYPs) and phase II glutathione-S-trans-
ferases (GSTs) andN-acetyltransferases. In particular, certain vari-
ants at CYPlAI, GSTM1 and GSTT1 genes have been related to
altered riskofcancers, such as ofthe lung, bladder, gastrointestinal
tract, skin, cervix and breast (Zhong et al, 1993; Alexandrie et al,
1994; Rebbeck et al, 1994; Warwick et al, 1994; Heagerty et al,
1996). In addition, germline polymorphisms in the same onco-
genes and tumour-suppressor genes may account for the differ-
ences in cancer susceptibility. In this sense, rare alleles ofHRAS1
and p53 may confer an increased risk of certain types of cancer,
including breast and ovarian cancer (Krontiris et al, 1993;
Runnebaum et al, 1995; Phelan et al, 1996).
Although endometrial carcinoma is acommon femalemalignancy,
relatively little attention has been given to genetic susceptibility
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factors. The present study was therefore undertaken to examine p53,
GSTM1, GSTTI1 and CYPlAI polymorphisms as potential molec-
ular markers ofendometrial carcinoma susceptibility.
MATERIALS AND METHODS
We analysed DNA extracted from 80 unrelated Caucasian patients
with histologically proven diagnosis of endometrial carcinoma,
recruited in the Department of Obstetrics and Gynecology at
the Hospital Universitari Matemo-Infantil Vall d'Hebron of
Barcelona. The protocol was approved by the institutional review
board and informed consent was obtained from all the patients
involved in the study. None of the patients had received radiation
therapy or hormonal treatment before surgery. Their ages ranged
from 45 to 82 years. Only five patients were premenopausal and
the remaining 75 were post-menopausal. The stage distribution of
the 80 patients, according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system was stage Ta
(13 cases), stage lb (19 cases), stage Ic (eight cases), stage Ila (11
cases), stage Ilb (nine cases), stage TIc (five cases), stage Illa (ten
cases), stage IlIb (three cases) and stage IlIc (two cases).
Histologically, 61 of the 80 patients had endometrioid-type carci-
nomas, whereas the remainder were 13 adenoacanthomas, two
papillary serous carcinomas, two clear cell carcinomas, one
papillar carcinoma and one mucinous carcinoma. Among all surgi-
cally collected endometrial carcinomas, 45 were well differenti-
ated (GI), 23 were moderately differentiated (G2) and 12 were
poorly differentiated (G3). The prevalence of the p53, GSTM1,
GSTT1 and CYPlAI polymorphisms studied were compared with
that observed in a control group comprising 60 unrelated women
from the same region, and with the same ethnic background,
attending theHospital Universitari Matemo-Infantil Vall d'Hebron
of Barcelona in the annual gynaecological cancer screening
programme. Controls were randomly selected from those women
who were free of clinical or histological malignancy. In addition,
each had no personal history of cancer. Their ages ranged from
44 to 76 years. DNA was extracted from fresh endometrial tissue
by proteinase K digestion and phenol-chloroform extraction
(Esteller et al, 1995).
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Table Association between p53, GSTM1, GSTT1 and CYPlAl genotypes
and endometrial cancer
Cases Controls
Genotype No. (%) No. (%)
p53PIN3
Wild-type 51 (63.7) 49 (81.6)
Heterozygous 27 (33.7) 10 (16.6)
Homozygous 2 (2.5) 1 (1.6)
ORa 2.5 (1.08-6.2) P= 0.03
p53 codon 72
Arg/Arg 36 (45) 29 (48.3)
Arg/Pro 36 (45) 23 (38.3)
Pro/Pro 8 (10) 8 (13.3)
P=0.69
GSTM1
Present 29 (36.2) 32 (53.3)
Null 51 (63.7) 28 (46.6)
OR 2.01 (0.9-4.2) P= 0.06
GSTT1
Present 61 (76.2) 48 (80)
Null 19 (23.7) 12 (20)
P=0.74
CYPlAl MspIRFLP
Wild-type 58 (72.5) 54 (90)
Heterozygous 21 (26.2) 6 (10)
Homozygous 1 (1.2)
ORa 3.67 (1.21-13.26) P= 0.02
CYPlAl IleNal
Wild-type 58 (72.5) 54 (90)
Heterozygous 20 (25) 5 (8.3)
Homozygous 2 (2.5) 1 (1.6)
ORa 3.67 (1.21-13.26) P = 0.02
aHeterozygous and homozygous mutant genotypes combined.
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Figure 2 CYPlAl gene polymorphisms analysed by PCR. (A)
Polymorphism in the 3'-end of the CYPlAl gene. The polymorphism was
studied by PCR followed by Mspl restriction enzyme digestion. Lane 1,
molecular weight marker (pGEM/Hinfl, Rsal and Sinl); lane 2, water control;
lanes 3, 6 and 8, wild-type homozygotes; lanes 4, 5 and 7, mutant
heterozygotes. Positions of the 340-, 200- and 140-basepair polymorphic
DNA fragments are shown in the right margin. (B) IleNal polymorphism in the
exon 7 of the CYPlAl gene. The polymorphism was studied by PCR
followed by Ncol restriction enzyme digestion. Lane 1, molecular weight
marker (pGEM/HinA, Rsal and Sinl; lane 2, water control; lanes 3-7, wild-
type homozygotes; lane 8, mutant heterozygote. Positions of the 195- and
163-basepair polymorphic DNA fragments are shown in the right margin
Figure 1 GSTM1 null genotype analysed by PCR and agarose gel
electrophoresis. A 157-bp DNA fragment corresponding to GSTM4 control
gene can be seen in all the PCR reactions. A 230-bp DNA fragment is only
present in samples containing the GSTM1 gene. Lane 1, molecular weight
marker (pGEM/Hinfl, Rsal and Sinl; lane 2, water control; lanes 3, 5 and 7,
GSTM1 non-nulled individuals; lanes 4, 6 and 8, GSTM1 nulled individuals
The 16-bp insertion in intron 3 of p53 (p53PIN3 allele) and
GSTM1 and GSTT1 null genotypes was determined by poly-
merase chain reaction (PCR) (Lazar et al, 1993; Zhong et al, 1993;
Pemble et al, 1994). Genotyping ofthe p53 codon 72 and CYPlAl
3'-end and exon 7 (isoleucineto valine substitution in residue 462)
polymorphisms was detected using PCR and restriction fragment
length polymorphism (RFLP) (De La Calle-Martin et al, 1990;
Hayashi et al, 1991; Shields et al, 1993).
The odds ratio (OR) ard 95% confidence intervals (CIs) were
calculated as a measure of the association between genotypes and
endometrial cancer. The StatXact-Turbo statistical package was
used to obtain exact P-values.
RESULTS
The table shows the frequency of p53, GSTM1, GSTT1 and
CYPlAl genotypes in control subjects and in patients with
endometrial carcinoma.
The p53PIN3 allele, collapsing the heterozygous and homozy-
gous categories, was significantly associated with endometrial
cancer with an OR of 2.5 (95% CI 1.08-6.2, P = 0.03). The
pS3PIN3 allele distribution in endometrial cancer patients,
according to age at onset, FIGO stage and histological type ofthe
tumours, was not significantly different. In addition, a statistically
significant association between the pS3PIN3 allele and an undif-
ferentiated cellular grade (G2 and G3) in endometrial carcinoma
was found (OR = 4.16; 95% CI 1.43-12.32, P = 0.006).
In contrast, the p53 codon 72 polymorphism, considering both
the heterozygous (ArgiPro) and homozygous (ProlPro) genotypes
ofthe minor allele, did not show a statistically significant associa-
tion with endometrial cancer risk (P = 0.73).
With respect to GSTM1 polymorphism, there was a slight
increase in the frequency ofGSTM1 null genotype in endometrial
carcinoma patients (63.7%) when compared with the control
group (46.6%), showing almost statistical significance (P = 0.06).
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A representative PCR analysis for GSTM1 genotyping is shown in
Figure 1. On the other hand, the GSTT1 null genotype in the
endometrial carcinoma group was not statistically significant
when compared with the control group (P = 0.74).
Finally, a statistically significant association was found between
endometrial carcinoma and both CYPlAl polymorphisms studied
(P = 0.02). The OR and 95% CI ofendometrial cancer risk for the
combined genotypes of heterozygous and homozygous rare
mutant alleles at the 3'-end and exon 7 of the CYPlAl gene was
the same: 3.67 (CI 1.21-13.26). No significant differences were
found in the distribution of both CYPlAI rare mutant alleles by
histological type. The MspI and NcoI RFLP analysis for CYPlAl
3'-end and exon 7 polymorphisms is illustrated in Figure 2.
DISCUSSION
Although endometrial carcinoma is a common female malignancy,
little is known about genetic factors in the aetiology ofthe disease.
Several studies have shown endometrial carcinoma to be a signifi-
cant component in a dominantly inherited cancer syndrome,
namely hereditary non-polyposis colorectal carcinoma; this
involves mutations in DNA mismatch repair genes (Marra et al,
1995). In addition, that mothers and sisters of endometrial cancer
patients have been found to have 2.7 times the risk ofendometrial
cancer as control subjects (Schildkraut et al, 1989).
To our knowledge, this is the first report of an association of
p53 and CYPlAI genetic polymorphisms with endometrial
cancer risk. In this study, we found an association between the
presence of the p53PIN3 allele and endometrial cancer risk. A
stronger significant association was found between endometrial
carcinoma risk and two genetic polymorphisms in 3'-end and
exon 7 of the CYPlAI gene. Finally, GSTM1 and GSTT1 null
genotypes and p53 codon 72 polymorphism data were not
significantly different in endometrial cancer patients and the
control group.
Germline polymorphisms of the tumour-suppressor gene p53,
such as the p53PIN3 allele, could be involved in endometrial
cancer risk because p53 gene alterations have been widely
described in endometrial tumours (Enomoto et al, 1993; Kihana et
al, 1995). In addition, the p53PIN3 allele has been previously
reported as associated with a higher ovarian cancer risk
(Runnebaum et al, 1995), although other studies have not found
this relation (Lancaster et al, 1995). Adding internal consistency of
our data, the frequencies for the p53PIN3 allele in our control
population are similar to those described (Lancaster et al, 1995;
Runnebaum et al, 1995). Owing to the undetermined functional
importance of the p53PIN3 allele and the few works reported,
large cancer case-control studies and assessment of intrinsic p53
activity ofthe variant form are required.
Finally, our finding that two CYPlAI genetic polymorphisms
are associated with endometrial cancer risk could be related to the
involvement of oestrogens in the development of endometrial
cancer. In premenopausal women, persistent anovulation, owing to
the polycystic ovary syndrome (Nisker et al, 1978) and ovarian
neoplasia, often causes an oestrogen-predominant milieu associ-
ated with the occurrence of endometrial cancers; in addition,
adipose tissues contribute to the formation of extraglandular
oestrogen (mainly oestrone), especially in perimenopause
(Lippman and Swain, 1992). Because oestrogen metabolism is
partially determined by cytochrome P-450 activity under the
control of CYPlAl and CYP1A2 genes, the polymorphisms
studied may influence the production of oestrogen 2-hydroxylated
metabolites (Schneider et al, 1984) and therefore individual
susceptibility to endometrial cancer. In a parallel way, the individ-
uals with rare CYPlAI genotypes could suffer alterations in the
metabolism of polycyclic aromatic hydrocarbons (known human
carcinogens widely distributed) to reactive mutagenic intermedi-
ates (Nebert, 1991), perhaps also contributing to the higher
endometrial cancer risk detected.
In conclusion, our preliminary data are consistent with a genetic
susceptibility to endometrial cancer associated with the p53PIN3
allele and two rare CYPlAI genotypes. In addition to suggesting
the contribution of polymorphisms in tumour-suppressor genes
and carcinogen-metabolism genes to be an enhanced cancer risk,
this study could provide a link with the epidemiological associa-
tion between oestrogen exposure and endometrial cancer. There-
fore, studies in larger populations of sporadic endometrial cancer
cases, in families with endometrial cancer aggregation with
different phenotypes, and in functional assessment of the geno-
types described are in progress.
ABBREVIATIONS
GSTM1, glutathione-S-transferase mu; GSTTI, glutathione-S-
transferase theta; CI, confidence interval; CYPlAI, cytochrome
P-450 lAI; p53PIN3, p53 gene insertional polymorphism in
intron 3; OR, odds ratio.
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